TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* A positive histological diagnosis of UC ≥3 months prior to entry into the study. If a histological diagnosis is not available but all signs and symptoms suggest UC, the subject's eligibility should be discussed with Pfizer.~* Active UC as defined by a score of ≥6 on the Mayo score.~* An endoscopic (by flexible sigmoidoscopy) sub-score of ≥2 on the Mayo score determined within 7 days of first dosing.~Exclusion Criteria:~* Subjects with UC, which is confined to a proctitis on a flexible sigmoidoscopy.~* Subjects who have had surgery as a treatment for UC or are likely to require surgery within the duration of the study.~* Subjects displaying clinical signs of ischemic colitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 0.03 mg/kg or placebo iv (Type: OTHER): None
- 0.1 mg/kg or placebo iv (Type: OTHER): None
- 0.3 mg/kg or placebo iv (Type: OTHER): None
- 1.0 mg/kg or placebo iv (Type: EXPERIMENTAL): None
- 3.0 mg/kg or placebo sc (Type: OTHER): None
- 10 mg/kg or placebo iv (Type: OTHER): None
- 0.3 mg/kg or placebo sc (Type: OTHER): None
- 0.1 mg/kg or placebo iv (multiple dose) (Type: OTHER): None
- 0.3 mg/kg or placebo iv (multiple dose) (Type: OTHER): None
- 3.0 mg/kg or placebo iv (Type: OTHER): None
- 0.1 mg/kg or placebo sc (Type: OTHER): None
- 0.3 mg/kg or placebo sc (multiple dose) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 2 diabetes and on either sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 3 months at stable dose~* Males and Females (of non-childbearing potential or who are using dual barrier methods of contraception) between 30 and 75 years of age~* HbA1c must be ≥7.5% and ≤10% at screening~* Fasting Plasma Glucose must be \<240 mg/dL at screening~Exclusion Criteria:~* History of type 1 diabetes~* History of diabetic ketoacidosis~* NYHA Class III or IV cardiac status or hospitalization for congestive heart failure within 6 weeks prior to Visit 1~* Treatment with any non-peroxisome proliferator-activated receptor (non-PPAR) antidiabetic agent, investigational or approved, other than metformin or permitted sulfonylureas within 3 months prior to screening~* Treatment with rosiglitazone, pioglitazone, or any PPAR investigational antidiabetic agent within 6 month prior to screening~* Body mass index \>45 kg/m2~* Fasting triglycerides \>500 mg/dL~* Uncontrolled hypertension (sitting systolic blood pressure \>160 mmHg and/or sitting diastolic blood pressure \>100 mmHg~* Presence of diabetic complications, which in the opinion of the investigator, would complicate the subject's participation in the study (i.e., require initiation of new medication)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- INT131 besylate 0.5 mg (Type: EXPERIMENTAL): INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
- INT131 besylate 1 mg (Type: EXPERIMENTAL): INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
- INT131 besylate 2 mg (Type: EXPERIMENTAL): INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
- INT131 besylate 3 mg (Type: EXPERIMENTAL): INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
- pioglitazone HCl 45 mg (Type: ACTIVE_COMPARATOR): pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
- placebo (Type: PLACEBO_COMPARATOR): placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Migraine with aura patients of both sexes.~* 18-60 years.~* 50-100 kg.~Exclusion Criteria:~* Headache less than 48 hours before the tests start~* Daily consumption of drugs of any kind other than oral contraceptives~* Pregnant or nursing women.~* Cardiovascular disease of any kind, including cerebrovascular diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Levcromakalim (Type: ACTIVE_COMPARATOR): None
- Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a short life expectancy (approximately 1 year or less) as estimated by the Investigator.~* The subject is 70 years of age or older if cognitively normal, or 55 years of age or older if terminal because of dementia.~* The subject's general health is adequate to undergo the study procedures.~Exclusion Criteria:~* The subject has a contraindication for PET.~* The subject has a known or suspected hypersensitivity/allergy to \[18F\]flutemetamol or to any of the excipients.~* The subject is unable to tolerate or cooperate with study procedures.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [18F] Flutemetamol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein~* Ability to comprehend and sign an informed consent document and complete study questionnaires in English~* Ability to record symptoms in accordance with the protocol~* Symptomatic varicose veins~* Visible varicose veins~Exclusion Criteria:~* Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP Classification of Venous Disorders).~* Leg obesity impairing the ability to access the vein to be treated and/or to apply post-procedure compression bandaging and stockings~* Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion~* Deep vein reflux unless clinically insignificant in comparison to superficial reflux~* Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings~* Reduced mobility~* Major surgery, prolonged hospitalization or pregnancy within 3 months of screening~* Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)~* Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions~* Current alcohol or drug abuse~* Pregnant or lactating women~* Women of childbearing potential not using effective contraception~* History of DVT, pulmonary embolism, or stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- polidocanol injectable foam, 0.125% (Type: EXPERIMENTAL): None
- polidocanol injectable foam, 0.5% (Type: EXPERIMENTAL): None
- polidocanol injectable foam, 1.0% (Type: EXPERIMENTAL): None
- Vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven GBM with central pathology review at Dartmouth-Hitchcock Medical Center (DHMC)~* Tumor specimen obtained at the time of surgery adequate for vaccination~* 18 years of age or older~* Karnofsky Performance Status 60% or greater~* Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10 9th/L~* Platelets greater than or equal to 100 x 10 9th/L~* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) less than or equal to 5 times the upper limits of normal (ULN)~* Total bilirubin less than or equal to 1.5 times ULN~* Serum creatinine less than or equal to 1.5 times ULN, OR estimated creatinine clearance greater than or equal to 60 mL/min~* No known immunosuppression other than chemo-related~* Negative HIV serologies~* No evidence of acute or chronic hepatitis on standard hepatitis C and B screening tests~* No chemotherapy within four weeks prior to leukapheresis~* Radiotherapy at outside institution is permitted if tissue was obtained at time of surgery at DHMC and patient is willing to follow-up per protocol~* Off steroids for at least two weeks before leukapheresis~* No second malignancies except non-melanoma skin cancer, and non-invasive cancer such at cervical CIS, superficial bladder cancer or breast CIS~* Negative serum or urine pregnancy test for women of childbearing potential~* No serious uncontrolled medical disorder or active infection~* All patients must give informed consent~* No history of clinical evidence of active autoimmune disease~Exclusion Criteria:~* Invasive cancers in the past 5 years~* Rheumatologic/autoimmune disease~* Pregnancy or unwillingness to remain on acceptable form of birth control during study~* Major cardiac, pulmonary, or other systemic disease; viral hepatitis; HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active and erosive rheumatoid arthritis with a DAS28 equal or greater than 3.2~* Inadequate response to a 1st anti-TNF~* Stable or no treatment with any DMARDs, or oral corticosteroids (\< or = to 10 mg/day of prednisone equivalent)during the preceding month~Exclusion Criteria:~* Counter-indication to other anti-TNF, abatacept, rituximab or tocilizumab~* Pregnancy~* Age \< 18 years~* Impossibility to give informed consent~* Impossibility to be followed for 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- arm 1 (2d anti-TNF): (Type: ACTIVE_COMPARATOR): infliximab, etanercept, adalimumab
- arm 2 (other biotherapy) (Type: ACTIVE_COMPARATOR): abatacept, rituximab or tocilizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age between newborn (1day) - 12 years~* Diagnosis of T. cruzi infection by:~  * Direct microscopic examination or~ * Conventional serology, at least two positive tests (ELISA, IIF or HAI)~* Written informed consent form by parent/ legal representative~* Children assent if \> 7 years~Exclusion Criteria:~* Pre-term (\< 37 weeks gestational age) or weight \< 2500 g~* Female subject who has reached menarche~* Subjects presenting any other acute or chronic health conditions, that in the opinion of the PI, may interfere with the PK, efficacy and/or safety evaluation of the study drug~* Known history of hypersensitivity or serious adverse reactions to nitro- imidazoles~* History of CD treatment with benznidazole or nifurtimox in the past~* Immunocompromised patients (clinical history compatible with HIV infection, primary immunodeficiency or prolonged treatment with corticosteroids or other immunosuppressive drugs)~* Abnormal laboratory test values at screening for the following parameters: total WBC count, platelet count, ALT, AST, total bilirubin and creatinine.~Exception for this criterion is considered for newborns with congenital Chagas Disease, for whom ALT/AST and bilirubin will not be considered exclusion criteria unless considered clinically significant by the investigator.~* Inability to comply with follow-up and/or not having a permanent address~* Any condition that prevents the subject from taking oral medication

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection~* Patients with a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL~* Stable highly active antiretroviral therapy (HAART) regimen for at least 12 weeks at screening~* In the investigator's opinion, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are not a valid treatment option, because of the patient's antiretroviral (ARV) treatment history, ARV resistance testing, medication-taking behavior, safety and tolerability concerns, or other patient-related factors~* Prescreening or/and screening plasma HIV-1 RNA greater than 1,000 copies/mL on HAART regimen at screening~Exclusion Criteria:~* Presence of any currently active conditions that fit the definition of the World Health Organization (WHO) Clinical Stage 4, with the following exceptions: stable cutaneous kaposi's sarcoma (ie, no internal organ involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the study time period, wasting syndrome~* Patients for whom an investigational ARV is part of the current regimen, with the following exceptions if applicable (depending on local regulatory approval): tenofovir, emtricitabine~* Previous or current use of enfuvirtide (ENF), tipranavir and/or DRV~* Life expectancy of less than 12 months~* Pregnant or breast-feeding females~* Any active clinically significant disease (eg, tuberculosis \[TB\], cardiac dysfunction, pancreatitis, acute viral infections) or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DRV/rtv 800/100 mg once daily (Type: EXPERIMENTAL): Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
- DRV/rtv 600/100 mg twice daily (Type: EXPERIMENTAL): One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mycosis fungoides~  * Stage IIB, IVA, or IVB~* Refractory or recurrent disease after at least 2 of the following prior therapies:~  * Local and/or systemic steroids~ * Retinoids~ * Interferon alfa~ * Local carmustine~ * Systemic chemotherapy~ * Psoralen and ultraviolet A (PUVA) light therapy~* No CNS involvement~* No erythroderma (T4)~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* Neutrophil count at least 1,500/mm\^3~* WBC at least 2,000/mm\^3~* Platelet count at least 75,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT and SGPT no greater than 2.5 times ULN~Renal~* Creatinine no greater than 1.5 times ULN~Cardiovascular~* LVEF normal by echocardiography or radionuclide angiocardiography~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 2 years after study participation~* No psychological, familial, sociological, or geographical condition that would preclude study compliance or follow-up~* No active infection requiring specific therapy (e.g., antibiotics or anti-HIV therapy)~* No other prior or concurrent primary malignant tumor except adequately treated carcinoma in situ of the cervix or squamous cell or basal cell skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* More than 2 weeks since prior immunotherapy~Chemotherapy~* See Disease Characteristics~* Prior systemic chemotherapy allowed provided all of the following conditions are met:~  * Cumulative anthracycline dose is less than 200 mg/m\^2~ * No allergy to anthracyclines~ * Prior methotrexate is low dose (i.e., weekly dose less than 30 mg)~* More than 2 weeks since prior chemotherapy~Endocrine therapy~* See Disease Characteristics~* No concurrent systemic steroids~Radiotherapy~* More than 2 weeks since prior radiotherapy~Surgery~* Not specified~Other~* Recovered from toxic effects of prior therapy, excluding alopecia~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Caelyx (Type: EXPERIMENTAL): doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Evaluating Etanercept in Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients who completed 16 weeks of treatment and have completed the baseline health care resource utilization questionnaire at screening in the ASCEND study 0881A3-402-WW from participating countries.~Exclusion criteria:~* Withdrawal from the ASCEND study for safety or any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etanercept (ETN) (Type: EXPERIMENTAL): Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of the ACRYSOF® IQ EDF Intraocular Lens (IOL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and sign an Independent Ethics Committee (IEC)/ Institutional Review Board (IRB) approved Informed Consent Form;~* Diagnosed with cataract in both eyes;~* Planned cataract removal by routine small incision surgery;~* Calculated IOL power is within the clinical study supply range (18.0-25.0 diopter (D) in 0.5 D steps);~* Preoperative regular astigmatism of less than 1.0 D.~Exclusion Criteria:~* Pregnancy or lactation current or planned during the course of the study;~* History of anterior segment (corneal, anterior chamber, sulcus) or posterior segment (uveal, vitreo-retinal) pathology including retinal vascular occlusive disease, retinal detachment or peripheral retinal laser photocoagulation, age-related macular degeneration (ARMD), glaucoma (uncontrolled or controlled with medication) or ocular hypertension, diabetic retinopathy, retinitis pigmentosa and any optic nerve pathology.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DFT015 (Type: EXPERIMENTAL): ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
- SN60WF (Type: ACTIVE_COMPARATOR): ACRYSOF® IQ Monofocal IOL, bilateral implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete